CELLJUVANT STUDY CELL-BASED ADJUVANT TECHNOLOGY

Serial Number 97263760
733

Registration Progress

Application Filed
Feb 11, 2022
Under Examination
May 30, 2023
Approved for Publication
Apr 4, 2023
Published for Opposition
Apr 4, 2023
Registered

Trademark Image

CELLJUVANT STUDY CELL-BASED ADJUVANT TECHNOLOGY

Basic Information

Serial Number
97263760
Filing Date
February 11, 2022
Published for Opposition
April 4, 2023
Drawing Code
3

Status Summary

Current Status
Active
Status Code
733
Status Date
May 16, 2025
Application
Pending
Classes
042 044

Rights Holder

Seqirus Inc.

03
Address
475 Green Oaks Parkway
Holly Springs, NC 27540

Ownership History

Seqirus Inc.

Original Applicant
03
Holly Springs, NC

Seqirus Inc.

Owner at Publication
03
Holly Springs, NC

Legal Representation

Attorney
Nancy Sabarra

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

38 events
Date Code Type Description Documents
Nov 24, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 17, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 16, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
May 16, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
May 16, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 3, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 26, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 26, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Nov 26, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 23, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 22, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 22, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
May 22, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 1, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 30, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 30, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 30, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 30, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 4, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 4, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 15, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 24, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 14, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 13, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 13, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 20, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 20, 2023 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jan 20, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Nov 23, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Nov 23, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Nov 23, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 27, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 27, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
May 27, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
May 23, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 17, 2022 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Feb 16, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 15, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Scientific research in the nature of conducting clinical trials for pharmaceutical preparations; scientific research in the nature of conducting clinical trials for flu vaccines; providing clinical trial research information about the results of clinical trials for flu vaccines; providing medical research and scientific research information in the field of flu vaccines and flu vaccine clinical trials; pharmaceutical research and development
Class 044
Medical information; pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical information services in the field of pharmaceuticals for preventing and treating viruses and respiratory disorders, including vaccines and pharmaceutical therapeutics

Additional Information

Design Mark
The mark consists of of the wording "CELLJUVANT STUDY" above the wording "CELL-BASED ADJUVANT TECHNOLOGY". Above the "J" in "CELLJUVANT" is a design of a circle with an arrow-like shape through the circle. The tip of the arrow is a design of a rocket ship. The "CELL" element of "CELLJUVANT" is in the color purple. The "JUVANT" element of "CELLJUVANT" and the word "STUDY" are in the color red. The rest of the wording in the mark is in the color gray. The circle element of the design is in the colors red and gray, and the arrow-like element of the design is red and purple with the rocket ship element being in the color purple.
Color Claim
The color(s) red, purple, and gray is/are claimed as a feature of the mark.

Classification

International Classes
042 044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"STUDY CELL-BASED ADJUVANT TECHNOLOGY"